Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension

被引：0
|
作者：
Reinisch, W. [1 ,2 ,3 ,4 ]
Gibson, P. [5 ]
Sandborn, W. J. [6 ]
Feagan, B. [7 ]
Marano, C. [8 ]
Strauss, R. [8 ]
Johanns, J. [8 ]
Zhang, H. [8 ]
Padgett, L. [8 ]
Adedokun, O. J. [8 ]
Colombel, J. -F. [9 ]
Collins, J. [10 ]
Rutgeerts, P. [11 ]
Tarabar, D. [12 ]
机构：
[1] Univ Klin Innere Med III, Vienna, Austria
[2] McMaster Univ, Vienna, Austria
[3] Univ Klin Innere Med III, Hamilton, Austria
[4] McMaster Univ, Hamilton, Austria
[5] Alfred Hosp, Melbourne, Vic, Australia
[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA
[7] Univ Western Ontario, Robarts Res Inst, Robarts Clin Trials Inc, London, ON, Canada
[8] Janssen R&D LLC, Spring House, PA USA
[9] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[10] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR USA
[11] Univ Hosp Gasthuisberg, Dept Haematol, Leuven, Netherlands
[12] Mil Med Acad, Dept Gastroenterol & Hepatol, Belgrade 11002, Serbia
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P307
引用
收藏
页码：S248 / S249
页数：2
相关论文
共 50 条
  • [1] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [2] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
  • [3] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
    Gibson, Peter R.
    Reinisch, Walter
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen W.
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
  • [4] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William J.
    Feagan, Brian G.
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul
    Tarabar, Dino
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
  • [5] Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies
    Adedokun, Omoniyi
    Xu, Zhenhua
    Marano, Colleen
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Ford, Joyce
    Zhou, Honghui
    Davis, Hugh
    Colombel, Jean-Frederic
    Reinisch, Walter
    Feagan, Brian
    Rutgeerts, Paul
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S517 - S517
  • [6] Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
    Gibson, Peter R.
    Feagan, Brian G.
    Sandborn, William J.
    Marano, Colleen
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Collins, Judith
    Tarabar, Dino
    Hebzda, Zbigniew
    Rutgeerts, Paul
    Reinisch, Walter
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2016, 7 : E168
  • [7] Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT-SC Induction
    Feagan, Brian
    Gibson, Peter
    Marano, Colleen
    Strauss, Richard
    Han, Chenglong
    Johanns, Jewel
    Zhang, Hongyan
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Collins, Judith
    Jarnerot, Gunnar
    Rutgeerts, Paul
    Sandborn, William
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S43 - S43
  • [8] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [9] Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction
    Sandborn, William
    Feagan, Brian
    Marano, Colleen
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter
    Collins, Judith
    Tarabar, Dino
    Hebzda, Zbigniew
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S502 - S503
  • [10] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Doug
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S21
12345